Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Sunday, June 1, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of non–small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline current and emerging approaches targeting HER2 in the management of advanced or metastatic NSCLC
- Evaluate emerging evidence and the potential place in the treatment algorithm for novel approaches targeting TROP2 in advanced or metastatic NSCLC
- Discuss potential strategies for optimizing outcomes, including toxicity management, with current and emerging therapies targeting HER2 and TROP2 in the management of advanced or metastatic NSCLC
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Consultant; Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Janssen, Merck & Co, Novartis, Takeda.
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Atlanta, GA
Disclosures: Advisor/Consultant: AbbVie, Amgen, AstraZeneca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Genentech, Gilead Sciences, Jazz, Johnson & Johnson, Novartis, Novacure, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda; DSMB: OncoC4; Research grant (paid to institution): Bayer, Boehringer Ingelheim, Daiichi Sankyo, Mythic, Prelude, Synthekine.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisory Board/Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi; Employment (Spouse): Boston Scientific; Grant/Research Support: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL Therapeutics; Stock (Spouse): Boston Scientific.
Christine M. Lovly, MD, PhD, FASCO
Associate Professor of Medicine
Division of Hematology-Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Consultant: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Guardant, Genentech, Gilead, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Takeda, Taiho, Tempus. Honoraria Recipient: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Guardant, Genentech, Gilead, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Takeda, Taiho, Tempus.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here